Akeso, Inc.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and nec… Read more
Market Cap & Net Worth: Akeso, Inc. (AKESF)
Akeso, Inc. (PINK:AKESF) has a market capitalization of $9.53 Billion ($9.53 Billion) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #2124 globally and #1527 in its home market, demonstrating a 21.68% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Akeso, Inc.'s stock price $10.34 by its total outstanding shares 921143176 (921.14 Million).
Akeso, Inc. Market Cap History: 2023 to 2025
Akeso, Inc.'s market capitalization history from 2023 to 2025. Data shows growth from $4.61 Billion to $9.53 Billion (47.05% CAGR).
Akeso, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Akeso, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.16x
Akeso, Inc.'s market cap is 4.16 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $4.61 Billion | $4.53 Billion | $2.03 Billion | 1.02x | 2.27x |
| 2024 | $8.84 Billion | $2.12 Billion | -$514.51 Million | 4.16x | N/A |
Competitor Companies of AKESF by Market Capitalization
Companies near Akeso, Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to Akeso, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Akeso, Inc. Historical Marketcap From 2023 to 2025
Between 2023 and today, Akeso, Inc.'s market cap moved from $4.61 Billion to $ 9.53 Billion, with a yearly change of 47.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $9.53 Billion | +7.79% |
| 2024 | $8.84 Billion | +91.90% |
| 2023 | $4.61 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Akeso, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.53 Billion USD |
| MoneyControl | $9.53 Billion USD |
| MarketWatch | $9.53 Billion USD |
| marketcap.company | $9.53 Billion USD |
| Reuters | $9.53 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.